Several years after the FDA's high-profile rejection of Lykos Therapeutics’ MDMA candidate for post-traumatic stress disorder, a new wave of developers is nearing the regulatory finish line with experimental psychedelic treatments for mental health conditions. But regulatory approval is, in many ways, just the beginning of a complex journey to market for these companies, should their drugs pass muster with the FDA.
In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with Fierce’s Donavyn Coffey to discuss her recent reporting on the commercial hurdles psychedelic drug developers may face on the path to market. They discuss how the report came together and explore some of the biggest challenges developers could face after FDA approval, from DEA scheduling and the logistics of administering treatments to the terminology used to describe the psychedelic experience.
To learn more about the topics in this episode: